Audio di episode ini mungkin rusak.
How to fix it?
TENTANG EPISODE INI
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Inggris
Amerika Serikat
CARI EPISODE TERDAHULU
Cari episode sebelumnya dari FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
EPISODE LAIN DALAM PODCAST INI
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
Sanggahan: Podcast dan karya seni yang disematkan pada halaman ini berasal dari U.S. Food and Drug Administration, Center for Drug Evaluation and Research, yang merupakan milik pemiliknya dan tidak berafiliasi atau didukung oleh Listen Notes, Inc.
Sunting
Terima kasih telah membantu agar basis data podcast tetap terbaru
